Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00194467 · ClinicalTrials.gov registry record · Phase 2
Suppression of Oral HHV8 Shedding With Valganciclovir
A Phase 2 study, sponsored by University of Washington.
- Completed
- Registry status
- Phase 2
- Development phase
- 32
- Enrollment target
NCT00194467 is a Phase 2 study that has completed, run by University of Washington. The registered enrollment target is 32 participants.
The verdict
NCT00194467, a Phase 2 study, has completed, sponsored by University of Washington.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 32 participants
- Enrollment target
Study Summary
The purpose of the study is to use valganciclovir to define the role of antiviral therapy in suppression of HHV-8 shedding in HHV-8 seropositive men. Our hypothesis is that valganciclovir will substantially reduce the frequency of detection and amount of HHV-8 in the mouth.
Interventions
- DRUG placebo
- DRUG valganciclovir
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2002-12 |
| Est. Completion | 2005-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00194467
The ClinicalTrials.gov registry entry for NCT00194467 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 32 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Washington, which has 1,048 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which placebo is the first listed.
NCT00194467 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00194467 about?
NCT00194467 is a clinical study titled "Suppression of Oral HHV8 Shedding With Valganciclovir". The purpose of the study is to use valganciclovir to define the role of antiviral therapy in suppression of HHV-8 shedding in HHV-8 seropositive men. Our hypothesis is that valganciclovir will substantially reduce the frequency of detection and amount of HHV-8 in the mouth.
What is the current status of trial NCT00194467?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 32 participants. The study started on 2002-12. Estimated completion is 2005-03.
What interventions are being tested in trial NCT00194467?
The interventions under investigation include: placebo (DRUG), valganciclovir (DRUG).
Who is sponsoring clinical trial NCT00194467?
This trial is sponsored by University of Washington, which has 1,048 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.